01—Abstract
Summary
Summary of the 8-K filed March 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (NYSE: COR) disclosed in a Form 8-K filed March 23, 2026 that it has signed a definitive agreement, dated March 21, 2026, to acquire the retina business of EyeSouth Partners for $1.1 billiona.
Upon closing, EyeSouth's affiliated retina physicians will join Cencora's Retina Consultants of America (RCA), a management services organization (MSO) that Cencora already operates. The deal extends Cencora's specialty care footprint in ophthalmology, a segment where RCA is positioned as a leading practice management platform. For investors, the most important financial points are the purchase price, the accretion outlook, and the guidance treatment.
Cencora expects the acquisition to be slightly accretive to adjusted diluted EPS, net of financing costs, in the first twelve months after closing. The company reaffirmed its fiscal 2026 guidance, but that guidance does not assume the transaction closes within fiscal 2026. The $1.1 billionb outlay is meaningful and is likely to be funded in part with debt, which ties directly to Cencora's stated de-leveraging plans and its commitment to maintaining an investment grade rating.
The transaction remains subject to customary closing conditions and required regulatory approvals, and the filing does not disclose a closing timetable. The filing is primarily a Regulation FD disclosure and does not include detailed financial information about EyeSouth Partners, such as revenue, EBITDA, or the financing structure. Investors should watch for the closing announcement, regulatory progress, and any updated financing or guidance commentary in future SEC filings.
02—Key points
Key Highlights
- Cencora signed a definitive agreement on March 21, 2026 to acquire EyeSouth Partners' retina business for $1.1 billion.
- EyeSouth's affiliated retina physicians will join Cencora's Retina Consultants of America (RCA), expanding the company's ophthalmology management services platform.
- Cencora expects the deal to be slightly accretive to adjusted diluted EPS, net of financing costs, in the first twelve months after closing.
- Cencora reaffirmed its fiscal 2026 financial guidance, which does not currently assume the transaction closes in fiscal 2026.
- Closing is subject to customary conditions and required regulatory approvals; no specific closing timeline was disclosed.
- Advisors include BofA Securities (lead financial advisor) and Citi for Cencora; EyeSouth is advised by Jefferies, a portfolio company of Olympus Partners is the seller.
- The filing flags de-leveraging plans and maintenance of an investment grade rating as relevant risk factors, implying debt-financed funding is a consideration.
03—Questions
Frequently Asked Questions
How much is Cencora paying for the EyeSouth Partners retina business?
Cencora agreed to acquire the EyeSouth Partners retina business for $1.1 billion, according to the press release furnished as Exhibit 99.1 to the 8-K.
Will this acquisition help Cencora's earnings?
Cencora expects the acquisition to be slightly accretive, net of financing costs, to its adjusted diluted EPS in the first twelve months after closing. The magnitude of accretion was not quantified in the filing.
Does the acquisition change Cencora's fiscal 2026 guidance?
No. Cencora reaffirmed its fiscal 2026 guidance, but that guidance does not currently contemplate the transaction closing within fiscal 2026.
When is the deal expected to close and what could prevent it?
The filing does not provide a specific closing date. Closing depends on customary conditions and required regulatory approvals. The forward-looking statements also cite risks such as failure to obtain approvals on the expected schedule, difficulty achieving expected synergies, and disruption or physician retention challenges after closing.
What does EyeSouth Partners bring to Retina Consultants of America?
EyeSouth Partners brings a strong regional network of affiliated retina physicians. Once the deal closes, these physicians will join RCA, which Cencora describes as a leading management services organization focused on retina care, clinical trials, and research.
04—Continue